Skip to main content

GeneFrontier to Make, Market Abcellute's Hepatocyte Tech to Japanese Drug Makers

NEW YORK (GenomeWeb News) — Welsh research company Abcellute today said it has signed an exclusive deal with microarray service provider GeneFrontier to manufacture, market, and distribute Abcellute’s hepatocyte cell-preservation products in Japan.
 
The agreement also gives Tokyo-based GeneFrontier rights to pen sub-license deals with the technology with pharma companies.    
 
Abcellute said its cell-preservation technology allows drug developers to evaluate drugs using hepatocytes that may be kept at non-freezing temperatures throughout a working week.
 
Financial terms of the deal were not released.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.